NCT03485209 2026-03-16
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
50 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03040999 2026-02-04
KEYNOTE-412
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT06056310 2025-09-29
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
Phase 1 Terminated
NCT03765918 2025-08-20
MK-3475-689
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04675333 2025-08-03
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
Phase 2 Active not recruiting
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT02990468 2023-03-15
BMX-HN
BioMimetix JV, LLC
Phase 1/2 Completed
NCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT04607642 2021-10-11
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
BioMimetix JV, LLC
Phase 2 Withdrawn
NCT02624999 2020-01-22
Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02555644 2019-02-15
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT00500760 2018-10-17
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Amgen
Phase 2 Completed
NCT00995293 2018-03-02
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
Sanofi
Phase 3 Completed
NCT01384799 2018-02-22
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Curis, Inc.
Phase 1 Completed
NCT01911598 2017-07-06
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Genentech, Inc.
Phase 1 Completed
NCT02107235 2017-06-23
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT00450138 2016-08-29
Open Label, Phase I ZD6474 Head and Neck Cancer Study
Sanofi
Phase 1 Completed
NCT00174837 2016-05-26
TRACE
Sanofi
Phase 3 Completed
NCT01161498 2016-02-08
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
BioVex Limited
Phase 3 Terminated
NCT02630264 2015-12-15
E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Guangzhou Double Bioproducts Co., Ltd
Phase 3 Unknown
NCT02429037 2015-04-29
P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Phase 2 Unknown
NCT02283489 2014-11-05
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
Chengdu Shi Endor Biological Engineering Technology Co., Ltd
Phase 2 Unknown
NCT01903018 2014-09-04
A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00
Piramal Enterprises Limited
Phase 2 Completed
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00261703 2012-05-11
Docetaxel in Head and Neck Cancer
Sanofi
Phase 2/3 Completed
NCT00415194 2011-06-28
A Study for Patients With Head and Neck Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00242762 2011-01-27
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
AstraZeneca
Phase 2 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed
NCT00094081 2010-02-15
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
Sanofi
Phase 3 Completed
NCT00337532 2010-02-04
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00357149 2009-12-07
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
Sanofi
Phase 2 Completed
NCT00521521 2009-12-07
TAX200006
Sanofi
Phase 2 Completed
NCT00772681 2009-12-07
Tax-Nazo
Sanofi
Phase 4 Completed
NCT00242749 2009-04-23
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00255476 2009-04-23
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
AstraZeneca
Phase 2 Completed
NCT00239304 2007-12-18
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
AstraZeneca
Phase 1/2 Completed